Pyxis Oncology, Inc. (PYXS) — 8-K Filings

8-K Filings (16)

• Pyxis Oncology Files 8-K for Regulation FD Disclosure — Dec 18, 2025 Risk: medium
  Pyxis Oncology, Inc. filed an 8-K on December 18, 2025, to report on events that occurred on the same date. The filing indicates it is for a Regulation FD Discl
• Pyxis Oncology Files 8-K — Aug 4, 2025 Risk: low
  Pyxis Oncology, Inc. filed an 8-K on August 4, 2025, to report other events. The filing does not contain specific details about the nature of these events, doll
• Pyxis Oncology Relocates Offices, Hints at Officer Changes — Jul 3, 2025 Risk: medium
  Pyxis Oncology, Inc. announced on July 1, 2025, a change in its principal executive offices to 321 Harrison Avenue, Boston, MA 02118. This filing also indicates
• Pyxis Oncology Files 8-K on Shareholder Matters — Jun 18, 2025 Risk: low
  Pyxis Oncology, Inc. filed an 8-K on June 18, 2025, to report on the submission of matters to a vote of its security holders. The filing details the company's c
• 8-K Filing — Mar 24, 2025
• Pfizer Acquires Pyxis Oncology for $1.1 Billion — Feb 26, 2025 Risk: medium
  Pyxis Oncology, Inc. announced on February 26, 2025, that it has entered into a definitive agreement to be acquired by Pfizer Inc. for $9.00 per share in cash,
• Pfizer to Acquire Pyxis Oncology — Feb 4, 2025 Risk: medium
  Pyxis Oncology, Inc. announced on February 4, 2025, that it has entered into a definitive agreement to be acquired by Pfizer Inc. The transaction is expected to
• Pyxis Oncology Files 8-K — Dec 19, 2024 Risk: low
  Pyxis Oncology, Inc. filed an 8-K on December 19, 2024, to report other events and financial statements. The filing does not contain specific details about the
• Pyxis Oncology Files 8-K — Nov 20, 2024 Risk: low
  Pyxis Oncology, Inc. filed an 8-K on November 20, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
• Pyxis Oncology Files 8-K for Shareholder Vote & Exhibits — Oct 23, 2024 Risk: low
  Pyxis Oncology, Inc. filed an 8-K on October 23, 2024, to report on the submission of matters to a vote of security holders and financial statements and exhibit
• Pyxis Oncology Reports Shareholder Vote — Jun 12, 2024 Risk: medium
  Pyxis Oncology, Inc. filed an 8-K on June 12, 2024, reporting on a matter submitted to a vote of its security holders on June 11, 2024. The filing does not disc
• Pyxis Oncology Announces Board Changes and Officer Compensation Updates — Jun 10, 2024 Risk: medium
  Pyxis Oncology, Inc. announced on June 10, 2024, a series of significant corporate events. These include the departure of certain officers and directors, the el
• Pyxis Oncology Files 8-K for Other Events — Mar 27, 2024 Risk: low
  Pyxis Oncology, Inc. filed an 8-K on March 27, 2024, to report other events and financial statements. The filing does not detail specific transactions or financ
• Pyxis Oncology Files 8-K on Financials — Mar 21, 2024 Risk: medium
  Pyxis Oncology, Inc. filed an 8-K on March 21, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disc
• Pyxis Oncology Halts Development of Two Programs, Cuts Workforce — Mar 13, 2024 Risk: medium
  Pyxis Oncology, Inc. announced on March 12, 2024, a strategic decision to discontinue its development programs for PYX-201 and PYX-301. This decision follows a
• Pyxis Oncology Enters Material Agreement, Sells Equity on Feb 26 — Feb 28, 2024 Risk: medium
  Pyxis Oncology, Inc. entered into a material definitive agreement on February 26, 2024, which also involved unregistered sales of equity securities. The company

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX